Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Jaume Puig-Junoy, Natàlia Pascual-Argente, Lluc Puig-Codina, Laura Planellas & Míriam Solozabal. (2018) Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review. Expert Review of Gastroenterology & Hepatology 12:12, pages 1251-1263.
Read now
Read now
Kirsten Y Westerhout, Walter Bouwmeester, Inge Duchesne, Marta Pisini, Marjanne A Piena, Francesco Damele, Beatrice Gueron, Maarten Treur & Jonathan Belsey. (2017) Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service. ClinicoEconomics and Outcomes Research 9, pages 163-172.
Read now
Read now
Articles from other publishers (9)
László Szilberhorn, Zoltán Kaló & Tamás Ágh. (2018) Cost-Effectiveness of Second-generation Direct-acting Antiviral Agents in Chronic HCV Infection: A Systematic Literature Review. Antiviral Therapy 24:4, pages 247-259.
Crossref
Crossref
Rodolfo Castro, Louise Crathorne, Hugo Perazzo, Julio Silva, Chris Cooper, Jo Varley-Campbell, Daniel Savignon Marinho, Marcela Haasova, Valdilea G. Veloso, Rob Anderson & Chris Hyde. (2018) Cost-effectiveness of diagnostic and therapeutic interventions for chronic hepatitis C: a systematic review of model-based analyses. BMC Medical Research Methodology 18:1.
Crossref
Crossref
X. Li, N. S. Chan, A. W. Tam, I. F. N. Hung & E. W. Chan. (2017) Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong. European Journal of Clinical Microbiology & Infectious Diseases 36:10, pages 1801-1809.
Crossref
Crossref
Madhumita Premkumar, Gagandeep S. Grover & Radha K. Dhiman. (2017) Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?. Journal of Clinical and Experimental Hepatology 7:3, pages 253-261.
Crossref
Crossref
Kohtaro Ooka, James J Connolly & Joseph K Lim. (2017) Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C. American Journal of Gastroenterology 112:6, pages 828-832.
Crossref
Crossref
Andrew J. Leidner, Harrell W. Chesson, Philip R. Spradling & Scott D. Holmberg. (2016) Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease. Applied Health Economics and Health Policy 15:1, pages 65-74.
Crossref
Crossref
Mary Geitona, Hara Kousoulakou, Ioannis Goulis, Spilios Manolakopoulos, Themistoclis Vasiliadis, Dimitrios Christodoulou, Charalabos Gogos, Spyridon Dourakis, Ioannis George Koskinas, Alexandra Papadokostopoulou, Aris Lathouris & George Papatheodoridis. (2017) Managing Hepatitis C Patients in Greece: A Budget Impact Analysis of Simeprevir plus Pegylated Interferon/Ribavirin Regimen at Early Stages of the Disease. Health 09:11, pages 1482-1493.
Crossref
Crossref
Roberto Nuño Solinís, Patricia Arratibel Ugarte, Ander Rojo & Yuri Sanchez Gonzalez. (2016) Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infectious Diseases and Therapy 5:4, pages 491-508.
Crossref
Crossref
Jagpreet Chhatwal, Tianhua He & Maria A. Lopez-Olivo. (2016) Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. PharmacoEconomics 34:6, pages 551-567.
Crossref
Crossref